Drug Trial Radar · NCT07441460
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
Mar 6, 2026
Primary completion
Aug 7, 2034
Study completion Aug 7, 2035
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.
Conditions
- Resectable HER2-positive Breast Cancer
Interventions
KN026Drug
In accordance with the protocol
HB1801Drug
In accordance with the protocol
TrastuzumabDrug
Intravenous infusion
PertuzumabDrug
Intravenous infusion
DocetaxelDrug
Intravenous infusion
EpirubicinDrug
Intravenous infusion
DoxorubicinDrug
Intravenous infusion
CyclophosphamideDrug
Intravenous infusion
CarboplatinDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- iDFSTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.